Vanda Pharmaceuticals
VNDA
164 hedge funds and large institutions have $759M invested in Vanda Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 34 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 56
0.79% less ownership
Funds ownership: 103.3% → 102.51% (-0.79%)
8% less funds holding
Funds holding: 179 → 164 (-15)
22% less capital invested
Capital invested by funds: $967M → $759M (-$208M)
27% less call options, than puts
Call options by funds: $661K | Put options by funds: $910K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$50.3M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$15.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.47M |
| 4 |
BlackRock
New York
|
+$7.12M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$22M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.7M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$10.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.07M |
| 5 |
First Manhattan
New York
|
-$6.04M |
VNDA Hedge Fund Activity: Q2 2019 in Review
164 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2019, worth a combined $759M — down 22% from $967M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of VNDA and 21 opened new positions — a net loss of 13 holders — while 56 trimmed existing stakes and 64 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $50.3M. The largest seller was Glenmede Trust, cutting an estimated $22M.
- 164 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2019, down from 179 in Q1 2019.
- Funds reported $759M of Vanda Pharmaceuticals stock for Q2 2019, down 22% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q2 2019 and 34 closed out, a net change of -13 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2019 was Armistice Capital, an estimated $50.3M added.
- The largest Vanda Pharmaceuticals seller in Q2 2019 was Glenmede Trust, an estimated $22M sold.
Based on aggregated 13F filings for Q2 2019.